LIGAND PHARMACEUTICALS INC Net Cash Provided by (Used in) Financing Activities in USD from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Ligand Pharmaceuticals Inc quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Ligand Pharmaceuticals Inc Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$4.75M, a 139% decline year-over-year.
  • Ligand Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2024 was $97.1M.
  • Ligand Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$59.9M, a 78.3% increase from 2022.
  • Ligand Pharmaceuticals Inc annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$276M, a 100% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

LIGAND PHARMACEUTICALS INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$4.75M -$16.9M -139% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q1 2024 $12.2M +$13M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
Q1 2023 -$775K +$170M +99.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 -$170M -$78.8M -86% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q1 2021 -$91.6M +$188M +67.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 -$279M -$127M -83.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 -$153M -$156M -4833% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q1 2018 $3.22M +$4.89M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 -$1.67M -$2.18M -426% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q1 2016 $511K -$270K -34.6% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q1 2015 $781K +$1.02M Jan 1, 2015 Mar 31, 2015 10-Q 2016-11-14
Q1 2014 -$241K +$9.15M +97.4% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q1 2013 -$9.39M -$8.55M -1018% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-07
Q1 2012 -$840K -$25.8M -103% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-08
Q1 2011 $24.9M Jan 1, 2011 Mar 31, 2011 10-Q/A 2012-11-14

LIGAND PHARMACEUTICALS INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $97.1M +$157M Jan 1, 2024 Dec 31, 2024 10-K 2025-02-28
2023 -$59.9M +$216M +78.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-28
2022 -$276M -$138M -100% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-28
2021 -$138M +$173M +55.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 -$311M +$175M +36% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$485M -$814M -248% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $329M +$336M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
2017 -$7.52M -$2.53M -50.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$4.99M -$13.4M -160% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $8.36M -$122M -93.6% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-01
2014 $130M +$146M Jan 1, 2014 Dec 31, 2014 10-K 2017-02-28
2013 -$16.5M -$20.4M -520% Jan 1, 2013 Dec 31, 2013 10-K 2016-11-14
2012 $3.92M -$26.1M -86.9% Jan 1, 2012 Dec 31, 2012 10-K 2015-02-23
2011 $30M +$30.2M Jan 1, 2011 Dec 31, 2011 10-K/A 2014-12-12
2010 -$159K Jan 1, 2010 Dec 31, 2010 10-K 2013-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.